Single User License
INR 136060
Site License
INR 272120
Corporate User License
INR 408180

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Myelofibrosis-Pipeline Review, H1 2015

Myelofibrosis-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Myelofibrosis-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Myelofibrosis-Pipeline Review, H1 2015', provides an overview of the Myelofibrosis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Myelofibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myelofibrosis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Myelofibrosis

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Myelofibrosis and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Myelofibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Myelofibrosis pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Myelofibrosis

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Myelofibrosis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Myelofibrosis Overview 9

Therapeutics Development 10

Pipeline Products for Myelofibrosis-Overview 10

Pipeline Products for Myelofibrosis-Comparative Analysis 11

Myelofibrosis-Therapeutics under Development by Companies 12

Myelofibrosis-Therapeutics under Investigation by Universities/Institutes 15

Myelofibrosis-Pipeline Products Glance 16

Late Stage Products 16

Clinical Stage Products 17

Early Stage Products 18

Myelofibrosis-Products under Development by Companies 19

Myelofibrosis-Products under Investigation by Universities/Institutes 21

Myelofibrosis-Companies Involved in Therapeutics Development 22

Acceleron Pharma, Inc. 22

Bristol-Myers Squibb Company 23

Celgene Corporation 24

CTI BioPharma Corp. 25

Gilead Sciences, Inc. 26

Incyte Corporation 27

Italfarmaco S.p.A. 28

Johnson & Johnson 29

KaloBios Pharmaceuticals, Inc. 30

MEI Pharma, Inc. 31

Nippon Shinyaku Co., Ltd. 32

Novartis AG 33

Onconova Therapeutics, Inc. 34

Pfizer Inc. 35

PharmaEssentia Corporation 36

Promedior, Inc. 37

Stemline Therapeutics, Inc. 38

Threshold Pharmaceuticals, Inc. 39

Myelofibrosis-Therapeutics Assessment 40

Assessment by Monotherapy Products 40

Assessment by Target 41

Assessment by Mechanism of Action 43

Assessment by Route of Administration 45

Assessment by Molecule Type 47

Drug Profiles 49

BMS-911543-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

buparlisib hydrochloride-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

erismodegib-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

evofosfamide-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

givinostat-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

glasdegib-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

imetelstat sodium-Drug Profile 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

INCB-39110-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

KB-004-Drug Profile 74

Product Description 74

Mechanism of Action 74

R&D Progress 74

LCL-161-Drug Profile 76

Product Description 76

Mechanism of Action 76

R&D Progress 76

momelotinib-Drug Profile 78

Product Description 78

Mechanism of Action 78

R&D Progress 78

NS-018-Drug Profile 81

Product Description 81

Mechanism of Action 81

R&D Progress 81

pacritinib-Drug Profile 82

Product Description 82

Mechanism of Action 82

R&D Progress 82

panobinostat-Drug Profile 84

Product Description 84

Mechanism of Action 84

R&D Progress 84

peginterferon alfa-2b-Drug Profile 90

Product Description 90

Mechanism of Action 90

R&D Progress 90

pomalidomide-Drug Profile 92

Product Description 92

Mechanism of Action 92

R&D Progress 92

pracinostat-Drug Profile 96

Product Description 96

Mechanism of Action 96

R&D Progress 96

PRM-151-Drug Profile 98

Product Description 98

Mechanism of Action 98

R&D Progress 98

rigosertib sodium-Drug Profile 100

Product Description 100

Mechanism of Action 100

R&D Progress 100

simtuzumab-Drug Profile 105

Product Description 105

Mechanism of Action 105

R&D Progress 105

SL-401-Drug Profile 107

Product Description 107

Mechanism of Action 107

R&D Progress 107

Small Molecules to Inhibit JAK for Oncology and Hematological Disorders-Drug Profile 109

Product Description 109

Mechanism of Action 109

R&D Progress 109

sotatercept-Drug Profile 110

Product Description 110

Mechanism of Action 110

R&D Progress 110

Myelofibrosis-Recent Pipeline Updates 112

Myelofibrosis-Dormant Projects 162

Myelofibrosis-Discontinued Products 163

Myelofibrosis-Product Development Milestones 164

Featured News & Press Releases 164

Dec 09, 2014: CTI BioPharma Announces Presentation of Data Demonstrating Pacritinib Overrides Stromal Mediated Resistance in FLT3-ITD Positive AML Cells 164

Dec 09, 2014: Promedior Presents Positive Phase 2 Data for PRM-151 in Myelofibrosis at ASH Annual Meeting 165

Dec 08, 2014: PRM-151 therapy well tolerated in patients with advanced myelofibrosis 166

Dec 06, 2014: CTI BioPharma Announces Comprehensive Kinome Analysis that Demonstrates Pacritinib Inhibits Kinases Linked to a Spectrum of Blood-Related Cancers 167

Dec 02, 2014: Incyte To Present Data On INCB039110 At at the 2014 American Society of Hematology Annual Meeting 168

Dec 01, 2014: CTI BioPharma Announces Data Presentation at the 56th American Society of Hematology Annual Meeting 169

Nov 06, 2014: Promedior Announces Presentation of Phase 2 Data on PRM-151 in Myelofibrosis at the Upcoming ASH Annual Meeting 170

Nov 03, 2014: Geron Announces Removal of Full Clinical Hold on Imetelstat IND 171

Nov 03, 2014: Promedior Receives Fast Track Designation for PRM-151 for the Treatment of Myelofibrosis 171

Sep 02, 2014: Promedior Receives U.S. Orphan Drug Designation for PRM-151 for the Treatment of Myelofibrosis 172

Appendix 174

Methodology 174

Coverage 174

Secondary Research 174

Primary Research 174

Expert Panel Validation 174

Contact Us 174

Disclaimer 175

List of Tables

Number of Products under Development for Myelofibrosis, H1 2015 10

Number of Products under Development for Myelofibrosis-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 13

Number of Products under Development by Companies, H1 2015 (Contd..1) 14

Number of Products under Investigation by Universities/Institutes, H1 2015 15

Comparative Analysis by Late Stage Development, H1 2015 16

Comparative Analysis by Clinical Stage Development, H1 2015 17

Comparative Analysis by Early Stage Development, H1 2015 18

Products under Development by Companies, H1 2015 19

Products under Development by Companies, H1 2015 (Contd..1) 20

Products under Investigation by Universities/Institutes, H1 2015 21

Myelofibrosis-Pipeline by Acceleron Pharma, Inc., H1 2015 22

Myelofibrosis-Pipeline by Bristol-Myers Squibb Company, H1 2015 23

Myelofibrosis-Pipeline by Celgene Corporation, H1 2015 24

Myelofibrosis-Pipeline by CTI BioPharma Corp., H1 2015 25

Myelofibrosis-Pipeline by Gilead Sciences, Inc., H1 2015 26

Myelofibrosis-Pipeline by Incyte Corporation, H1 2015 27

Myelofibrosis-Pipeline by Italfarmaco S.p.A., H1 2015 28

Myelofibrosis-Pipeline by Johnson & Johnson, H1 2015 29

Myelofibrosis-Pipeline by KaloBios Pharmaceuticals, Inc., H1 2015 30

Myelofibrosis-Pipeline by MEI Pharma, Inc., H1 2015 31

Myelofibrosis-Pipeline by Nippon Shinyaku Co., Ltd., H1 2015 32

Myelofibrosis-Pipeline by Novartis AG, H1 2015 33

Myelofibrosis-Pipeline by Onconova Therapeutics, Inc., H1 2015 34

Myelofibrosis-Pipeline by Pfizer Inc., H1 2015 35

Myelofibrosis-Pipeline by PharmaEssentia Corporation, H1 2015 36

Myelofibrosis-Pipeline by Promedior, Inc., H1 2015 37

Myelofibrosis-Pipeline by Stemline Therapeutics, Inc., H1 2015 38

Myelofibrosis-Pipeline by Threshold Pharmaceuticals, Inc., H1 2015 39

Assessment by Monotherapy Products, H1 2015 40

Number of Products by Stage and Target, H1 2015 42

Number of Products by Stage and Mechanism of Action, H1 2015 44

Number of Products by Stage and Route of Administration, H1 2015 46

Number of Products by Stage and Molecule Type, H1 2015 48

Myelofibrosis Therapeutics-Recent Pipeline Updates, H1 2015 112

Myelofibrosis-Dormant Projects, H1 2015 162

Myelofibrosis-Discontinued Products, H1 2015 163

List of Figures

Number of Products under Development for Myelofibrosis, H1 2015 10

Number of Products under Development for Myelofibrosis-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 12

Comparative Analysis by Clinical Stage Development, H1 2015 17

Assessment by Monotherapy Products, H1 2015 40

Number of Products by Top 10 Targets, H1 2015 41

Number of Products by Stage and Top 10 Targets, H1 2015 41

Number of Products by Top 10 Mechanism of Actions, H1 2015 43

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 43

Number of Products by Top 10 Routes of Administration, H1 2015 45

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 45

Number of Products by Top 10 Molecule Types, H1 2015 47

Number of Products by Stage and Top 10 Molecule Types, H1 2015 47

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Acceleron Pharma, Inc.

Bristol-Myers Squibb Company

Celgene Corporation

CTI BioPharma Corp.

Gilead Sciences, Inc.

Incyte Corporation

Italfarmaco S.p.A.

Johnson & Johnson

KaloBios Pharmaceuticals, Inc.

MEI Pharma, Inc.

Nippon Shinyaku Co., Ltd.

Novartis AG

Onconova Therapeutics, Inc.

Pfizer Inc.

PharmaEssentia Corporation

Promedior, Inc.

Stemline Therapeutics, Inc.

Threshold Pharmaceuticals, Inc.

Myelofibrosis Therapeutic Products under Development, Key Players in Myelofibrosis Therapeutics, Myelofibrosis Pipeline Overview, Myelofibrosis Pipeline, Myelofibrosis Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com